A Pilot Study To Examine The Effects Of Ticagrelor To Protect Against Type 2 Diabetes-Induced Vascular Damage

Inclusion Criteria: 1. Provision of informed consent prior to any study specific procedures. 2. A previous or new diagnosis of type 2 diabetes mellitus, document by one of following criteria:1）Hemoglobin A1c of ≥6.5% at diagnosis;2) Fasting plasma glucose (FPG) ≥126mg/dL (7.0 mmol/L);3) Two-hour plasma glucose≥200 mg/dL (11.1 mmol/L) during an oral glucose tolerance test (OGTT);4) with classic symptoms of hyperglycemia or hyperglycemic crisis, a random plasma glucose≥200mg/dL (11.1 mmol/L)( confirmed by repeat testing) 3. A previous or new diagnosis of stable CAD according to ICD 10 for at least 6 months, document by following criteria: 1) Stable angina; 2) No AMI or NSTE-ACS within 1 month;and(or) 3) EKG with ischemic ST-segment and(or) T-wave change; and(or)4) coronory artery stenosis ≥50% viewed by coronary CTA or coronary angiography 4. No medication history of clopidogrel/ticagrelor for at least 1 months 5. Female or male, and any race, aged≥18 years, not pregnant. Exclusion Criteria: 1. Blood pressure\>160/100 mm Hg; 2. Hypercholesterolemia(LDL-c \>240mg/dl); 3. Hemoglobin A1c ≥ 10%; 4. Platelet count less than 10\*10\^9/L or hemoglobin \<10 g/dL; 5. Intolerance or allergy to clopidogrel/ticagrelor or any of the excipients; 6. Patient with known inflammatory conditions or those on anti-inflammatory drug therapy; 7. Second and third degree atrioventricular block; 8. chronic obstructive lung disease or asthma; 9. Creatinine\>2 mg/dl; 10. Malignancy; 11. Moderate or severe hepatic impairment; 12. History of intracranial haemorrhage; 13. Active pathological bleeding; 14. Pregnancy or lactation; 15. Any condition that increases the risk for noncompliance or being lost to follow-up; 16. Medicine history of potent CYP3A4 inhibitor(ketoconazole, clarithromycin,etc.); 17. No provision of informed consent.